Xoma Corp XOMA
We take great care to ensure that the data presented and summarized in this overview for XOMA Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding XOMA
View all-
Bvf Inc San Francisco, CA3.63MShares$97.2 Million3.57% of portfolio
-
Black Rock Inc. New York, NY512KShares$13.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA464KShares$12.4 Million0.0% of portfolio
-
Morgan Stanley New York, NY317KShares$8.49 Million0.0% of portfolio
-
Opaleye Management Inc. Boston, MA250KShares$6.69 Million1.29% of portfolio
-
Geode Capital Management, LLC Boston, MA182KShares$4.88 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA156KShares$4.18 Million0.03% of portfolio
-
State Street Corp Boston, MA145KShares$3.87 Million0.0% of portfolio
-
Stonepine Capital Management, LLC Bend, OR126KShares$3.36 Million2.67% of portfolio
-
Tls Advisors LLC Miami, FL119KShares$3.19 Million7.15% of portfolio
Latest Institutional Activity in XOMA
Top Purchases
Top Sells
About XOMA
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Insider Transactions at XOMA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 24
2025
|
Bvf Partners L P > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
149,975
-100.0%
|
$3,899,350
$26.1 P/Share
|
|
Jan 24
2025
|
Bvf Partners L P > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
500,742
-41.43%
|
$13,019,292
$26.1 P/Share
|
|
Jan 08
2025
|
Bradley Sitko Chief Investment Officer |
BUY
Open market or private purchase
|
Indirect |
150
+50.0%
|
$3,750
$25.75 P/Share
|
|
Jan 08
2025
|
Bradley Sitko Chief Investment Officer |
BUY
Open market or private purchase
|
Indirect |
82
+50.0%
|
$2,050
$25.6 P/Share
|
|
Jan 08
2025
|
Bradley Sitko Chief Investment Officer |
BUY
Open market or private purchase
|
Direct |
313
+50.0%
|
$7,825
$25.6 P/Share
|
|
Dec 31
2024
|
Bradley Sitko Chief Investment Officer |
BUY
Open market or private purchase
|
Direct |
300
+3.17%
|
$7,500
$25.9 P/Share
|
|
Nov 13
2024
|
Owen Hughes Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
21,881
-38.48%
|
$634,549
$29.95 P/Share
|
|
Nov 13
2024
|
Thomas M. Burns SVP, Finance & CFO |
SELL
Open market or private sale
|
Direct |
9,775
-40.18%
|
$283,475
$29.94 P/Share
|
|
Nov 11
2024
|
Owen Hughes Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
53,360
+48.41%
|
-
|
|
Nov 11
2024
|
Thomas M. Burns SVP, Finance & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,773
+42.22%
|
-
|
|
May 15
2024
|
Natasha Hernday |
BUY
Grant, award, or other acquisition
|
Direct |
3,035
+50.0%
|
-
|
|
May 15
2024
|
Matthew D Perry |
BUY
Grant, award, or other acquisition
|
Direct |
6,070
+25.36%
|
-
|
|
May 15
2024
|
Jack L Wyszomierski |
BUY
Grant, award, or other acquisition
|
Direct |
6,070
+32.63%
|
-
|
|
Oct 03
2023
|
Bradley Sitko Chief Investment Officer |
BUY
Open market or private purchase
|
Direct |
250
+4.27%
|
$3,250
$13.89 P/Share
|
|
Oct 02
2023
|
Owen Hughes Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+22.22%
|
$13,000
$13.83 P/Share
|
|
Oct 02
2023
|
Bradley Sitko Chief Investment Officer |
BUY
Open market or private purchase
|
Direct |
1,500
+21.9%
|
$21,000
$14.25 P/Share
|
|
Sep 26
2023
|
Owen Hughes Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,499
+49.99%
|
$34,986
$14.43 P/Share
|
|
Sep 25
2023
|
Owen Hughes Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1
+50.0%
|
$14
$14.65 P/Share
|
|
May 31
2023
|
Bradley Sitko Chief Investment Officer |
BUY
Open market or private purchase
|
Indirect |
1,500
+19.44%
|
$25,500
$17.1 P/Share
|
|
May 24
2023
|
Owen Hughes Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1,032
+34.04%
|
$23,736
$23.79 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 71.1K shares |
|---|---|
| Grant, award, or other acquisition | 15.2K shares |
| Open market or private purchase | 845 shares |
| Open market or private sale | 682K shares |
|---|